Hepatitis after gene therapy, what are the possible causes?

Abstract

AbstractHepatitis is a common adverse event following gene therapy for haemophilia, often associated with a loss of transgene expression. Investigating the potential causes and implications of this is crucial for the overall success of treatment. Gene therapy trials using adeno‐associated virus (AAV) vectors have demonstrated promising results marked by increases in factor FVIII and FIX levels and reductions in episodes of bleeding. However, hepatocellular injury characterised by elevations in alanine aminotransferases (ALT) has been noted. This liver injury is typically transient and asymptomatic, posing challenges in determining its clinical significance. Proposed causes encompass immune‐mediated responses, notably T cell cytotoxicity in response to the AAV vector, direct liver injury from the viral capsid or transcribed protein via the unfolded protein response and pre‐existing liver conditions. Liver biopsy data conducted years post‐gene therapy infusion has shown sinusoidal infiltration without significant inflammation. The overall safety profile of gene therapy remains favourable with no evidence drug‐induced liver injury (DILI) based on Hy's Law criteria. Essential pre‐therapy monitoring and identifying patients at high risk of liver injury should involve liver function tests and non‐invasive fibroscans, while novel blood‐based biomarkers are under exploration. Further research is required to comprehend the mechanisms underlying transaminitis, loss of transgene expression and long‐term effects on the liver, providing insights for optimising gene therapy for haemophilia.